Successor for Chairman
03.04.2013 - Swiss Basilea Ltd has proposed Martin Nicklasson as the successor to Chairman Werner Henrich, whose term will end in June.
Dr Nicklasson is a high-profile pharmaceutical business professional with longstanding operational and board experience. Born in 1955, the Swedish pharmacist is Associate Professor at the Department of Pharmaceutics, University of Uppsala. Dr Nicklasson has held numerous leadership and executive positions in commercial operations and drug development at AstraZeneca Plc. He was the President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB and serves as a Board Member in a number of biotech companies in Europe and the US.